HCQ Shows Promise in Reducing Proteinuria in Primary Glomerular Diseases: Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-18 15:30 GMT | Update On 2025-08-19 06:01 GMT

A new study published in BMC Nephrology found that hydroxychloroquine (HCQ) therapy demonstrated a trend toward reducing proteinuria in patients with primary glomerular diseases. Importantly, HCQ did not significantly impact estimated glomerular filtration rate (eGFR), indicating preserved kidney function during treatment. The study also highlighted HCQ’s favorable safety profile, making it a promising adjunct therapy in managing proteinuria in these patients.

Proteinuria is a key marker of kidney damage in glomerular diseases and is linked to progression to chronic kidney failure. Conventional treatments often involve immunosuppressants with variable efficacy and potential adverse effects. The potential role of HCQ, traditionally used in autoimmune conditions, offers an alternative pathway targeting inflammatory and immunological mechanisms involved in glomerular injury.

While the reduction in proteinuria was a trend rather than statistically definitive, the findings encourage further clinical trials to clarify HCQ’s efficacy and long-term impact on kidney outcomes. The favorable safety observed in this study supports continued exploration of HCQ as a low-risk therapeutic option in nephrology.

Reference:

BMC Nephrology. (2025). Hydroxychloroquine therapy and proteinuria in primary glomerular diseases. https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-042XX-X [API]

Article Source : BMC Nephrology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Shravani Dali

Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

HCQ Shows Promise in Reducing Proteinuria in Primary Glomerular Diseases: Study

Similar News

Steroidal MRAs Ineffective and Risky in Kidney Transplant Recipients: Study

World's first clinical trial showing lubiprostone aids kidney function, finds study

Air Pollution Linked to Accelerated Kidney Function Decline, Reveals Large-Scale Study

Abelacimab Cuts Bleeding Risk in AF Patients Regardless of Kidney Function: AZALEA-TIMI 71 Analysis

Melatonin Improves Sleep and Some Quality-of-Life Measures, Not BP among Hemodialysis Patients: Study

SGLT2 Inhibitors Linked to Lower Anemia Risk in Type 2 Diabetes, Suggests Study

Urinary NGAL Emerges as a Reliable Biomarker in Nephrotic Syndrome: Study Finds

Women With Metabolic Syndrome Face Higher Odds of Overactive Bladder: Study